IP Library Granted Patent US 10,201,526
Granted Patent B2
US 10,201,526 · App. 15/276,739 · Granted Feb 12, 2019

Compositions and methods for inhibiting the growth of neisseria gonorrhoeae

Inventors: Jennifer Edwards (Westerville, OH); Alexander Zukiwski (Clarksburg, MD)
Assignees: Research Institute at Nationwide Children's Hospital; Ohio State Innovation Foundation
A61K31/415A61K31/546A61K31/7036A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,201,526
App. No.
15/276,739
Granted
Feb 12, 2019
Kind
B2
Abstract

Compositions and methods for preventing and treating Neisseria gonorrhoeae infection with AR-12 alone or in combination with antibiotics are provided.

Claims (13)

1. A method of reducing the amount of viable Neisseria gonorrhoeae in a human having a cervical epithelial cell infection with Neisseria gonorrhoeae comprising administering 2-amino-N-(4-(5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-2-yl)phenyl)acetamide (AR-12) to a human infected with Neisseria gonorrhoeae.

2. The method of claim 1 , wherein the amount of AR-12 administered to the infected human is sufficient to achieve a blood or tissue concentration of at least about 1 to 12 μM.

3. The method of claim 2 , wherein the amount of AR-12 administered to the infected human is sufficient to achieve a blood or tissue concentration of at least about 10 μM.

4. The method of claim 1 , wherein AR-12 is administered to infected cervical tissue.

5. The method of claim 4 , wherein AR-12 contacts the infected cervical tissue for at least about 3 hours.

6. The method of claim 5 , wherein AR-12 contacts the infected cervical tissue from about 3 to about 24 hours.

7. The method of claim 1 , further comprising administering an antibiotic to the infected human.

8. The method of claim 7 , wherein the antibiotic is selected from the group consisting of ceftriaxone and gentamicin.

9. The method of claim 8 , wherein the antibiotic is provided in an amount from about 5 μg/ml to about 100 μg/ml.

10. The method of claim 2 , wherein the amount of AR-12 administered to the infected human is from about 10 to 1600 mg once or twice daily.

11. The method of claim 1 , wherein AR-12 is administered in an amount from about 1 to about 1000 mg.

12. The method of claim 11 , wherein the amount of AR-12 is from about 1 to about 500 mg.

13. The method of claim 11 , wherein the amount of AR-12 is from about 10 to about 200 mg.

Assignments (4)
CONFIRMATORY LICENSE Recorded Dec 20, 2018
From: OHIO STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 047968/0626 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2018
From: ARNO THERAPEUTICS, INC.
To: OHIO STATE INNOVATION FOUNDATION
Reel/Frame 044653/0937 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2017
From: EDWARDS, JENNIFER
To: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
Reel/Frame 042505/0400 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2017
From: ZUKIWSKI, ALEXANDER
To: ARNO THERAPEUTICS, INC.
Reel/Frame 042505/0440 →
Continuity (2)
Provisional Application 62233723 · Sep 28, 2015
Related Publication 20170087130A1 · Mar 30, 2017